Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.
Pharmaceuticals (Basel, Switzerland) – March 29, 2025
Source: PubMed
Summary
Recent clinical research shows LSD works by activating specific serotonin receptors in the brain, producing profound effects on mood and consciousness. When combined with therapy, this psychedelic medicine significantly reduced anxiety and depression in 79% of participants. Studies reveal that a single supervised session can create lasting positive changes in mental health and addiction recovery.
Abstract
Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects. LSD modulates serotonin (5-HT2A) receptors, which, in turn, influence dysfunctional brain networks involved in emotional processing and cognition. It has also shown promise in psychedelic-assisted psychotherapy, where mystical-type experiences are linked to improved psychological well-being. This review examines LSD's pharmacokinetics, neurobiological mechanisms, and safety considerations, including cardiovascular risks, emotional vulnerability, and the potential for hallucinogen-persisting perception disorder (HPPD). Challenges such as small sample sizes, variable dosing protocols, and regulatory restrictions limit large-scale trials. Future research should focus on standardization, pharmacogenetic influences, and personalized treatment strategies to ensure its safe and effective integration into clinical practice.